⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Form 8-K
sec.gov
RVMDW
RVMD
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
prnewswire.com
ACRS
ALC
AMGN
BCRX
BIIB
BMY
CRSP
CTRA
CYTK
DASH
EXAS
GILD
GSK
INCY
JNJ
KDP
LULU
MRNA
NBIX
NVS
OCGN
ORCL
PFE
REGN
ROST
RVMD
SNOW
SRPT
STRL
TGTX
TMO
TRMB
TSLA
TXG
VRTX
XOM
ZBRA
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Investors Urged to Contact Levi & Korsinsky For Information Before August 10, 2026 - Erasca, Inc. (ERAS)
accessnewswire.com
ERAS
RVMD
REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
businesswire.com
REPL
RVMD
BeOne Medicines y Revolution Medicines anuncian una colaboración para el desarrollo clínico y la comercialización en determinados mercados asiáticos
businesswire.com
ONC
RVMD
BeOne Medicines et Revolution Medicines annoncent un accord de collaboration portant sur le développement clinique et la commercialisation régionale
businesswire.com
ONC
RVMD
Lost Money on Erasca, Inc. (ERAS)? Contact Levi & Korsinsky to Join Class Action Before August 10, 2026
accessnewswire.com
ERAS
RVMD
Erasca, Inc. (ERAS) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 10, 2026
accessnewswire.com
ERAS
RVMD